Section
Compounding
503A and 503B pharmacies, shortages and telehealth supply.
- Oct 30The National Law Review
Peptides - HHS Announces Limited Enforcement Discretion for Compounding of Six Peptides
By Maren Holt - Oct 30Boxing Insider
Six Peptides From Our January Guide Just Got a Federal Green Light. Licensed Fighters Still Cannot Touch Them
By Maren Holt - Oct 30StreetInsider
HHS announces interim enforcement policy on six compounded peptides
- Oct 30FinancialContent
CDT Equity Welcomes U.S. Regulatory Development Supporting Expanded Access to Compounded Peptides
By Maren Holt - Oct 30PravdaReport
HHS Grants Enforcement Discretion for Six Peptides in 503A Compounding Pharmacies
By Maren Holt 5 Things to Know About HHS's Interim Peptide Compounding Policy
- Oct 29PakTribune
US peptide policy opens compounding debate without granting drug approval
- Oct 29Everyday Health
Unproven Peptides Championed by RFK Jr. Can Now Be Made by Compounders
HHS Draft Policy Eases Enforcement on 6 Compounded Peptides
- Oct 29citybuzz -
Certified-PEP Releases 2026 Research Peptide Supplier Comparison, Highlighting Transparency Gaps
By Maren Holt RFK Jr backs compounding of six unapproved peptides in new policy
By Maren HoltHHS Outlines Conditional Enforcement Discretion for 6 Compounded Peptides
By Maren Holt- Oct 29Stock Titan
A new U.S. policy creates a conditional route for two of six peptides to be taken by mouth
- Oct 29STAT
STAT+: Pharmalittle: We’re reading about a new policy for compounding peptides, a PBM disclosure rule, and more
By Maren Holt - Oct 29Clarin.com
Which unapproved peptides were cleared by RFK Jr.? What the 6 compounds do and their health risks
- Oct 29BioSpace
HHS clears compounding pharmacies to manufacture 6 unapproved peptides
- Oct 29Yahoo Finance
The Precision Peptide Company Quadruples U.S. Telehealth Formulary to 16 Prescription Therapies Across Seven Therapy Areas
By Maren Holt - Oct 29Medscape
Compounded GLP-1s Coformulated With B12, Other Additives
- Oct 28NPR
Trump administration will allow pharmacies to make popular peptides
- Oct 28TradingView
HIMS Stock Jumps 5% After HHS Temporarily Clears Compounding Of Six Peptides
- Oct 28SSBCrack
HHS Temporarily Allows Compounding Pharmacies to Produce Six Unapproved Peptides
By Maren Holt - Oct 28Bloomberg.com
US to Allow Compounding of Six Peptides in Temporary Plan
By Maren Holt - Oct 28UA.NEWS
HHS in the US will temporarily not take action on compounding six peptides — STAT News
HHS Temporarily Allows Compounding Pharmacies To Make Six Peptides
By Maren Holt- Oct 28Demokratis.co.id
HHS Allows Pharmacies to Compound Six Unapproved Peptides
By Maren Holt - Oct 28Cirebon Times
HHS Allows Six Unapproved Peptides for Pharmacy Compounding
By Maren Holt - Oct 28STAT
HHS moves to allow compounding of some unapproved peptides
- Oct 28STAT
STAT+: HHS moves to allow compounding of some unapproved peptides
By Maren Holt - Oct 28AOL.com
RFK Jr. takes shortcut to make some unapproved peptides available for use
- Oct 28NBC News
RFK Jr. takes shortcut to make some peptides more widely available
- Oct 28TradingView
US Health Secretary Kennedy opens access to some unapproved peptides
By Maren Holt - Oct 27FinancialContent
Majority Stake in Apollo Wellness Centers Acquired; Launching on Doc-Rx Telehealth and U.S. Peptide Platform with Stand Up Wellness Clinics for Sibannac, Inc. (Stock Symbol: SNNC)
Ozari Health Named Cheapest Place to Buy Compounded Tirzepatide Online for 2026
- Oct 27TradingView
BellChild Co.,Ltd. Estimates – TSE:503A
- Oct 27Labcompare
What Labs Need to Know about Peptides in 2027
Telehealth and Automation Are Reshaping Compounding
By Maren Holt- Oct 26PEPTI
PEPTI lists NAD+ injection at $249 as recall touches category
By Maren Holt - Oct 26Medical Daily
Apothecary Pharma recalls 22 compounded tirzepatide vials over sterility doubts
By Maren Holt - Oct 24SSBCrack
Lab analysis finds Brooklyn bodega 'retatrutide' vial held phenylacetic acid
By Maren Holt - Oct 24Dallas News
FDA classifies Apothecary Pharma compounded tirzepatide recall as Class II
By Maren Holt
- Oct 23Law360
Eli Lilly, Novo Nordisk Antitrust Suit Remains Dismissed
By Maren Holt - Oct 23KRQE
FDA posts Class II recall of Apothecary Pharma tirzepatide, NAD+ vials
- Oct 23FinancialContent
Crescent Bioresearch reports DSIP lot below 5 EU per vial endotoxin
By Maren Holt - Oct 2395.5 WSB
Recall alert: Some GLP-1 injections recalled over sterility concerns
- Oct 22BioPharma Dive
Compounder recalls copycat tirzepatide in FDA Class II action
By Maren Holt - Oct 22Science-Based Medicine
Science-Based Medicine faults FDA panel vote on six compounded peptides
By Maren Holt - Oct 21drugscontrol.org
Nationwide Recall of Compounded Tirzepatide Injections Sparks Fresh Safety Concerns Over Weight-Loss Medicines
By Maren Holt - Oct 21Pharmacy Times
Pharmacy Times says USP standards matter more as peptides go mainstream
By Maren Holt - Oct 21FinancialContent
Crescent Bioresearch posts MOTS-c lot at 36.6 EU per vial endotoxin
- Oct 21DVM360
Wedgewood recalls nearly 4000 compounded veterinary products over drug potency concerns
By Maren Holt Apothecary Pharma recalls compounded tirzepatide and NAD+ vials over sterility concerns
- Oct 21ConsumerAffairs
Apothecary Pharma recalls compounded tirzepatide vials over sterility assurance
By Maren Holt - Oct 21ThePrint
FDA classifies Apothecary Pharma tirzepatide recall as Class II over sterility
By Maren Holt - Oct 21Medical Daily
FDA logs Class II recall of Apothecary Pharma compounded tirzepatide vials
By Maren Holt - Oct 21NewsBytes
Apothecary Pharma recalls 22 compounded tirzepatide injection vial lot codes
By Maren Holt - Oct 21Around Prague
Compounded Tirzepatide Recall: Which Vials Are Affected and What Is Known
- Oct 21Baller Alert
FDA classifies Apothecary Pharma compounded tirzepatide recall as Class II
- Oct 21Patch
GLP-1 Drug Recalled Nationwide Due To Possible Health Risks
By Maren Holt - Oct 20Los Angeles Times
FDA classifies Apothecary Pharma compounded tirzepatide recall as Class II
By Maren Holt - Oct 20Fox Business
Apothecary Pharma recalls 22 tirzepatide vials and one NAD+ vial nationwide
By Maren Holt - Oct 20Marietta Daily Journal
Innovation Compounding opens new 503A facility in Kennesaw, Georgia
By Maren Holt - Oct 20Hudson Valley Post
FDA classifies Apothecary Pharma compounded tirzepatide recall as Class II
By Maren Holt - Oct 20Florida Today
Report says GLP-1 supply has shifted from shortage to stability
By Maren Holt - Oct 20pharmaphorum
Apothecary Pharma recalls compounded tirzepatide vials over sterility concerns
- Oct 19Newsmax
Newsmax reports hospitalizations linked to peptide use
- Oct 19Pharmacy Times
Pharmacy Times briefs pharmacists on shifting peptide compounding rules
- Oct 19Medical Daily
FDA cites Houston RX for 14 sterility problems behind tirzepatide recall
- Oct 18USA Today
Mochi Health cuts compounded semaglutide price to $60 a month
By Maren Holt - Oct 17Peter Attia MD
The [almost] unbelievable relationship between “big pharma” and gray-market peptides
- Oct 17Meteo.gr
FDA proposes restrictions on bulk compounding of weight-loss drugs
- Oct 16Yahoo Creators
Switching from compounded semaglutide to tirzepatide? A doctor explains what to know first
- Oct 16Meridian Star
The Evolving Research Landscape of the Frag 176–191, Mod GRF 1–29, and Ipamorelin Blend
- Oct 16American Press
CJC-1295 and GHRP-2: Dual Growth Hormone Secretagogue Strategy in Molecular Science
By Maren Holt - Oct 16Newsweek
Newsweek op-ed cites 990 FDA adverse-event reports on compounded semaglutide
By Maren Holt - Oct 16MedShadow Foundation
FDA enforcement report lists recalls of compounded semaglutide, tirzepatide, NAD+ and sermorelin
- Oct 16Yahoo Finance
DataMeds AI plans peptide compounding expansion via Corexa Health
By Maren Holt - Oct 16Medscape
Medscape: photos show many self-described branded GLP-1 users on compounded drugs
By Maren Holt - Oct 15TradingView
Hims & Hers shares rise 6% as peptide compounding policy reaches OMB
By Maren Holt - Oct 15New York Post
FDA inspectors found mold and insects at two Chinese GLP-1 ingredient plants
- Oct 15JD Supra
Law firm analysis says prescribing architecture is next compounding question after Empower
